Valeant Pharmaceuticals: Aggressive Accounting Games
Below are the available bulk discount rates for each individual item when you purchase a certain amount
Register as a Premium Educator at hbsp.harvard.edu, plan a course, and save your students up to 50% with your academic discount.
Publication Date:
March 31, 2017
Source:
Stanford Graduate School of Business
In February 2008, as world markets slid deeper into economic decline, J. Michael Pearson joined Valeant Pharmaceuticals, a specialty pharmaceuticals company, then based in a quiet suburb of southern California. By August 2015, the stock price peaked, valuing the company at nearly $90 billion, up from $2 billion in 2008. In that time, Valeant had made over 100 acquisitions with total revenues growing from roughly $750 million in 2008 to over $10 billion in 2015. The explosive growth of Valeant in just seven-and-a-half years was not without purpose.
If you’d like to share this PDF, you can purchase copyright permissions by increasing the quantity.
Copyright © 2021 Harvard Business School Publishing. All rights reserved. Harvard Business Publishing is an affiliate of Harvard Business School.
Valeant Pharmaceuticals: Aggressive Accounting Games
Research & References of Valeant Pharmaceuticals: Aggressive Accounting Games|A&C Accounting And Tax Services
Source